{"prompt": "['Herceptin IV and pertuzumab and trastuzumab FDC SC will be administered by staff with', 'immediate access to emergency equipment who are trained to monitor for, and respond to,', 'medical emergencies.', \"Please refer to the Herceptin Investigator's Brochure for the most recent data related to the\", 'risk of ARRs, allergic-like reactions, and hypersensitivity reactions.', '5.1.2.2', 'Pulmonary Events', 'Severe pulmonary events have been reported with the use of the Herceptin IV formulation in', 'the post-marketing setting. These events have occasionally been fatal. They may occur as', 'part of an ARR or with delayed onset. In addition, cases of interstitial lung disease, including', 'lung infiltrates, ARDS, pneumonia, pneumonitis, pleural effusion, respiratory distress, acute', 'pulmonary oedema, and respiratory insufficiency have been reported with Herceptin IV.', 'These events have been most common with the first infusion, and their severity has', 'decreased with subsequent infusions. Serious reactions have been treated successfully with', 'supportive therapy, such as oxygen, -agonists, and corticosteroids. Acute respiratory', 'distress syndrome has been reported with a fatal outcome.', \"Please refer to the Herceptin Investigator's Brochure for the most recent data related to the\", 'risk of pulmonary events.', '5.1.2.3', 'Symptomatic Left Ventricular Systolic Dysfunction', 'Heart failure (NYHA Class Il - IV) has been observed in patients who have received', 'Herceptin IV and/or SC alone or in combination with docetaxel following anthracycline', '(doxorubicin or epirubicin)-containing chemotherapy. This event may be moderate to severe', 'and has been associated with death. Risk factors for Herceptin-associated LVSD include', 'increased age, concomitant administration with anthracyclines, and declining LVEF while on', 'Herceptin treatment. If symptomatic cardiac failure develops during treatment, it should be', 'treated with standard medications for this purpose.', 'The rates of cardiac dysfunction observed in large Herceptin adjuvant trials in EBC are < 4%', 'with event rates comparable across the studies. In Study BO22227 (see Section 1.2.4), the', 'proportion of patients who experienced a significant decrease in LVEF (defined as a drop in', 'LVEF 10 percentage points to a value of < 50%) was similar in each treatment arm (12', '[4.2%] patients in Herceptin IV and 11 [3.8%] patients in Herceptin SC).', 'Because the half-life of Herceptin IV is approximately 28 - 38 days, Herceptin may persist in', 'the circulation for up to 7 months after the last dose of Herceptin. Patients who receive', 'anthracyclines after the last dose of Herceptin may possibly be at increased risk of LVSD. If', 'possible, physicians should avoid anthracycline-based therapy for up to 27 weeks', \"(7 months) after stopping Herceptin. If anthracyclines are used, the patient's cardiac function\", 'should be monitored carefully.', 'Most patients who developed heart failure in the Phase III trials of Herceptin IV or SC in', 'MBC and EBC improved with standard medical treatment. This treatment included diuretics,', 'cardiac glycosides, and/or ACE inhibitors. The majority of patients with cardiac symptoms', 'and evidence of a clinical benefit of Herceptin treatment continued on weekly therapy with', 'Herceptin without experiencing additional clinical cardiac events.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '61 / Protocol MO40628, Version 12'][\"Please refer to the Herceptin Investigator's Brochure for the most recent data related to the\", 'risk of LVSD.', '5.1.3', 'Reproductive Risks Associated with Pertuzumab and Trastuzumab', 'Reproductive toxicity was identified during nonclinical studies with Perjeta. Perjeta', 'administered to pregnant cynomolgus monkeys during organogenesis led to delayed renal', 'development, oligohydramnios, and embryo-foetal deaths. However, reproductive toxicity', 'studies with trastuzumab conducted in female cynomolgus monkeys revealed no', 'trastuzumab-related embryotoxicity or effects on foetal development. There are no clinical', 'studies of trastuzumab or pertuzumab in pregnant women. IgGs are known to cross the', 'placental barrier. In the post-marketing setting, cases of oligohydramnios, some associated', 'with fatal pulmonary hypoplasia of the foetus, have been reported in pregnant women', 'receiving Herceptin. Therefore, neither pertuzumab or trastuzumab should be used during', 'pregnancy unless the potential benefit for the mother outweighs the potential risk to the', 'foetus.', 'Due to these risks, female participants of childbearing potential in this study are tested for', 'pregnancy prior to study entry and must undergo pregnancy testing during the study and,', 'guided be the half-life of Herceptin IV, up to seven months after their last study treatment.', 'Pregnancies in female participants or partners of male participants will be monitored. Further,', 'participants of childbearing potential (defined as post-menarchal, has not reached a post-', 'menopausal state [post-menopausal defined as 12 continuous months of amenorrhea with', 'no identified cause other than menopause], and has not undergone surgical sterilization', '[removal of ovaries and/or uterus]), must remain abstinent (refrain from heterosexual', 'intercourse) or use non-hormonal contraceptive methods with a failure rate of <1% per year,', 'or two effective non-hormonal contraceptive methods during the study treatment periods and', 'for 7 months after the last dose of study treatment and must refrain from donating eggs', 'during the same period. Women who have had a tubal ligation do not require additional', 'contraception. The definition of childbearing potential may be adapted for alignment with', 'local guidelines or requirements.', 'Men with female partners of childbearing potential, or with pregnant female partners,', 'participating in the study must remain abstinent or use a condom during the study treatment', 'periods and for seven months after the last dose of study treatment to avoid exposing the', 'embryo. All male participants must also refrain from donating sperm during this same period.', 'Examples of non-hormonal contraceptive methods with a failure rate of < 1% per year', 'include bilateral tubal ligation, male sterilization (with appropriate post-vasectomy', 'documentation of the absence of sperm in the ejaculate) and copper IUDs.', 'The reliability of sexual abstinence should be evaluated in relation to the duration of the', 'clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g.,', 'calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not', 'acceptable methods of contraception.', 'Alternatively, two of the following effective forms of contraception may be used instead:', 'Placement of non-hormonal IUD or intrauterine system', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '62 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}